Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia

PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, <i>P</i> = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, <i>P</i> = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, <i>P</i> = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, <i>P</i> = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.